Pernas S, et al. - Researchers conducted this review to summarize the background and latest evidence on the current management of early stage, HER2-positive breast cancer and present novel perspectives on its management. They found that overall survival in metastatic breast cancer remarkably improved with the dual HER2 blockade, but led to small benefits in progression-free survival in patients with early-stage disease. Response to treatment and prognosis may be determined with the biologic heterogeneity within the HER2-positive disease. Findings suggested that different therapeutic approaches may be beneficial for different subgroups of patients with HER2-positive breast cancer.